Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

NCT05618366 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Lymphoma, Non-Hodgkin
Diffuse Large B Cell Lymphoma
Follicular Lymphoma

Interventions

DRUG: Venetoclax
DRUG: Tazemetostat

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]
[object Object]